Virpax Confirms Results With U.S. Army With Probudur For Combat Care Study, Showing Incision Pain Reduction In Rat Model, Aiming To Reduce Opioid Need; Long Duration Pain Control Demonstrated Up To 5 Days

Author: Benzinga Newsdesk | February 13, 2025 05:02pm

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced the completion of the full study that followed the initial Probudur™ pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).

The USAISR is the U.S. Department of Defense's premier research organization for developing solutions for trauma and critical care challenges in combat casualties. This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain. The surgical procedures and assessments were identical to those in the pilot study. The study compared Probudur with free bupivacaine and EXPAREL®.

Various concentrations of Probudur were injected into the tissue around the incision site as well as a saline solution for the control group. The doses of Probudur showed reduction in incision-induced pain behaviors. "These positive results are consistent with what we at Virpax have previously observed and we are encouraged by these findings," commented Jatinder Dhaliwal, Chief Executive Officer of Virpax.

Probudur is being developed to achieve the overall goal of safe and effective pain control during the perioperative period and to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channels, preventing pain signals from reaching the brain. In preclinical studies, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six (6) days.

Posted In: VRPX